Optiscan needs a new Chairman

Before the dust settles it’s time the brokers behind the key shareholding stakes should have an eye on the excellent future in front of Optiscan. It’s great timing to appoint a strong, truly skilled independent Chairman who can work alongside local staff and deal with a world leader like Zeiss. This will unlock the potential available to the company and create the trust which will elevate market capitalisation to the level deserved.
A comparison to Cochlear (COH) is in order. In 1967 Graeme Clark started researching the possibilities of an electric implantable hearing device. The first commercial implant was effected in 1982. Sales grew from $72m (1996) to $1240m (2017). Cochlear is now a $10.6 billion company chaired by Rick Holliday-Smith (also the Chairman of ASX Ltd.).
Now maybe we can’t afford Mr. Holliday-Smith today but an appointment of the same calibre will help us all go forward